IL158561A0 - Crystalline form of omerprazole - Google Patents

Crystalline form of omerprazole

Info

Publication number
IL158561A0
IL158561A0 IL15856102A IL15856102A IL158561A0 IL 158561 A0 IL158561 A0 IL 158561A0 IL 15856102 A IL15856102 A IL 15856102A IL 15856102 A IL15856102 A IL 15856102A IL 158561 A0 IL158561 A0 IL 158561A0
Authority
IL
Israel
Prior art keywords
omeprazole
crystalline form
methoxy
disclosed
omerprazole
Prior art date
Application number
IL15856102A
Other languages
English (en)
Original Assignee
Lek Tovarna Farmacevtskih
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20432882&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL158561(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lek Tovarna Farmacevtskih filed Critical Lek Tovarna Farmacevtskih
Publication of IL158561A0 publication Critical patent/IL158561A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IL15856102A 2001-04-25 2002-04-24 Crystalline form of omerprazole IL158561A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SI200100111A SI20875A (sl) 2001-04-25 2001-04-25 Kristalna oblika omeprazola
PCT/IB2002/001350 WO2002085889A1 (en) 2001-04-25 2002-04-24 Crystalline form of omeprazole

Publications (1)

Publication Number Publication Date
IL158561A0 true IL158561A0 (en) 2004-05-12

Family

ID=20432882

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15856102A IL158561A0 (en) 2001-04-25 2002-04-24 Crystalline form of omerprazole

Country Status (26)

Country Link
US (2) US20040122056A1 (sl)
EP (1) EP1390360B1 (sl)
JP (1) JP4455815B2 (sl)
KR (1) KR20030094358A (sl)
CN (1) CN1531533B (sl)
AT (1) ATE346063T1 (sl)
AU (1) AU2002307892B2 (sl)
BG (1) BG108287A (sl)
BR (1) BR0209103A (sl)
CA (1) CA2445251C (sl)
CZ (1) CZ20032911A3 (sl)
DE (1) DE60216273T2 (sl)
HR (1) HRP20030853B1 (sl)
HU (1) HUP0303928A2 (sl)
IL (1) IL158561A0 (sl)
MX (1) MXPA03009789A (sl)
NO (1) NO20034715L (sl)
NZ (1) NZ528917A (sl)
PL (1) PL366471A1 (sl)
RS (1) RS50880B (sl)
RU (1) RU2286991C2 (sl)
SI (2) SI20875A (sl)
SK (1) SK13192003A3 (sl)
UA (1) UA77671C2 (sl)
WO (1) WO2002085889A1 (sl)
ZA (1) ZA200307988B (sl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8815916B2 (en) 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
ES2246149B1 (es) * 2004-07-02 2007-06-01 Esteve Quimica, S.A. Formas solidas de la sal magnesica de s-omeprazol y procedimientos para su preparacion.
EP1904064A4 (en) * 2005-07-07 2009-12-02 Reddys Lab Ltd Dr OMEPRAZOLE OF FORM B
EP1988163B1 (en) * 2006-02-22 2012-06-27 International Institute of Cancer Immunology, Inc. Hla-a*3303-restricted wt1 peptide and pharmaceutical composition comprising the same
WO2008067037A2 (en) 2006-10-05 2008-06-05 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
EP2086543A2 (en) 2006-10-27 2009-08-12 The Curators of the University of Missouri Compositions comprising at least one acid labile proton pump inhibiting agents, optionally other pharmaceutically active agents and methods of using same
WO2008092939A2 (en) 2007-01-31 2008-08-07 Krka, Tovarna Zdravil, D.D., Novo Mesto Process for the preparation of optically pure omeprazole via salt formation with a chiral amine or treatment with an entiomer converting enzyme and chromatographic separation
WO2010134099A1 (en) 2009-05-21 2010-11-25 Cadila Healthcare Limited One pot process for preparing omeprazole and related compounds
CN102786513A (zh) * 2011-05-18 2012-11-21 中国医学科学院药物研究所 奥美拉唑晶e型物质及制备方法与在药品和保健品中应用
CN102351846B (zh) * 2011-09-07 2012-08-22 周晓东 一种新的奥美拉唑钠化合物及其药物组合物
KR101459088B1 (ko) * 2012-08-02 2014-12-02 대화제약 주식회사 알-라베프라졸, 이의 금속염의 제조방법
WO2023079094A1 (en) * 2021-11-05 2023-05-11 Cinclus Pharma Holding AB (publ) Polymorphs of the hydrochloride salt of linaprazan glurate
WO2024075017A1 (en) 2022-10-04 2024-04-11 Zabirnyk Arsenii Inhibition of aortic valve calcification

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) * 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
IE67187B1 (en) * 1990-06-15 1996-03-06 Merck & Co Inc A crystallization method to improve crystal structure and size
SE510666C2 (sv) * 1996-12-20 1999-06-14 Astra Ab Nya Kristallmodifikationer
SI20019A (sl) * 1998-07-13 2000-02-29 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Izboljšan postopek sinteze 5-metoksi -2-/(4-metoksi-3,5-dimetil-2-piridil)metil/ sulfinil-1H-benzimidazola
US6166213A (en) * 1998-08-11 2000-12-26 Merck & Co., Inc. Omeprazole process and compositions thereof
UA72748C2 (en) * 1998-11-10 2005-04-15 Astrazeneca Ab A novel crystalline form of omeprazole
AUPQ841800A0 (en) * 2000-06-28 2000-07-20 Biomolecular Research Institute Limited Truncated egf receptor
US6627646B2 (en) * 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs

Also Published As

Publication number Publication date
BR0209103A (pt) 2004-07-13
UA77671C2 (en) 2007-01-15
SI1390360T1 (sl) 2007-04-30
CA2445251C (en) 2011-01-04
CN1531533B (zh) 2012-07-18
SI20875A (sl) 2002-10-31
JP2004526786A (ja) 2004-09-02
AU2002307892B2 (en) 2008-04-17
EP1390360A1 (en) 2004-02-25
US20060079560A1 (en) 2006-04-13
EP1390360B1 (en) 2006-11-22
PL366471A1 (en) 2005-02-07
DE60216273T2 (de) 2007-05-31
BG108287A (bg) 2005-04-30
RU2003133213A (ru) 2005-05-10
ZA200307988B (en) 2004-10-14
US20040122056A1 (en) 2004-06-24
KR20030094358A (ko) 2003-12-11
SK13192003A3 (sk) 2004-03-02
CA2445251A1 (en) 2002-10-31
JP4455815B2 (ja) 2010-04-21
HRP20030853B1 (en) 2011-11-30
ATE346063T1 (de) 2006-12-15
MXPA03009789A (es) 2005-03-07
NO20034715D0 (no) 2003-10-21
HRP20030853A2 (en) 2005-08-31
US7553856B2 (en) 2009-06-30
DE60216273D1 (de) 2007-01-04
NZ528917A (en) 2006-02-24
NO20034715L (no) 2003-12-10
WO2002085889A1 (en) 2002-10-31
HUP0303928A2 (hu) 2004-03-01
CZ20032911A3 (en) 2004-06-16
RS50880B (sr) 2010-08-31
CN1531533A (zh) 2004-09-22
YU84003A (sh) 2006-08-17
RU2286991C2 (ru) 2006-11-10

Similar Documents

Publication Publication Date Title
HRP20030853A2 (en) Crystalline form of omeprazole
WO1999008500A3 (en) New crystalline form of omeprazole
MY127871A (en) Omeprazole sodium salt
CA2357744A1 (en) Potassium salt of (s)-omeprazole
WO1998054171A8 (en) Novel form of s-omeprazole
AR010361A1 (es) "S-OMEPRAZOL [ENANTIoMERO S DE 5-METOXI-2-[[(4--METOXI-3,5-DIMETIL-2-PIRIDINIL)-METIL]SULFINIL]-1H-BENCIMIDAZOL], EN UNA FORMA NEUTRA NO SALINA, PROCESO PARA SU PREPARACION, COMPOSICION FARMACEUTICA, Y SU USO PARA LA MANUFACTURA DE MEDICAMENTOS"
MY111737A (en) Use of omeprazole as an antimicrobial agent.
JP2002535401A5 (sl)
MY118199A (en) Process for preparing omeprazole
CA2474246A1 (en) Alkylammonium salts of omeprazole and esomeprazole
JP2007504223A5 (sl)
SE0302382D0 (sv) New salts II
JP2007504222A5 (sl)
YU32301A (sh) Novi kristalni oblik omeprazola
US20050131026A1 (en) Use of proton pump inhibitors for the treatment of airway disorders
MY118724A (en) New crystalline form of omeprazole
JP2005523298A (ja) 非心臓性胸痛の治療のためのプロトンポンプ阻害剤の使用